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Abstract 
Paraneoplastic syndromes of hepatocellular carcinoma (HCC) are not uncommon. 
However, the prognosis is poor and follow-up and improvement of paraneoplastic 
syndromes with treatment have been reported rarely. We report a successful case in an 
aged man of a massive HCC with paraneoplastic syndrome, treated by combined 
intraarterial chemotherapy and hepatic resection. Paraneoplastic syndrome 
(erythrocytosis and hyperlipidemia) was monitored throughout the treatment and 
erythropoietin (EPO) mRNA also was analyzed in the resected liver. The hemoglobin level 
and serum levels of EPO and total cholesterol (T-cho) decreased dramatically with 
treatment, along with a decrease in serum levels of α-fetoprotein and protein induced by 
vitamin vitamin K absence II (PIVKA-II). Semiquantitative reverse transcription 
polymerase chain reaction (RT-PCR) revealed that the residual cancer expressed EPO RNA 
but the nontumor tissue did not. This was a rare case of paraneoplastic syndrome of HCC 
that was treated successfully. This case indicates that paraneoplastic syndrome reflected 
tumor progression and that serum levels of both EPO and T-cho might be used as tumor 
markers. 
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Introduction 
Hepatocellular carcinoma (HCC) sometimes manifests with a variety of paraneoplastic 
syndrome, such as hypoglycemia [1, 2], erythrocytosis [1, 3], hypercalcemia [1, 4, 5], 
hypercholesterolemia [1], and thrombocytopenia [6]. Although the reported frequency of 
paraneoplastic syndrome varies from 1 to 40%, most HCC patients with paraneoplastic 
syndrome have massive tumors and increased levels of α-fetoprotein (AFP) [1–3, 6]. The 
symptoms of some paraneoplastic syndromes, such as hypoglycemia, may be detected 
early and must be treated as soon as possible. However other paraneoplastic syndromes, 
such as erythrocytosis and hyperlipidemia, are silent and often detected too late, unless 
recognized by chance. Thus, treatment of HCC patients with paraneoplastic syndrome 
has proved difficult, despite therapies such as surgery and chemotherapy, including 
transarterial chemoembolization [2, 3]. Furthermore, these therapies were sometimes 
restricted by complications and liver function. These cases with delayed detection died 
without sufficient treatment. Here, we report a successful case of combined therapy, 
including intraarterial neoadjuvant chemotherapy using CDDP and surgery, for an aged 
man with a massive HCC with erythrocytosis and hypercholesterolemia. The serum levels 
of erythropoietin (EPO) and total cholesterol (T-cho) were monitored throughout the 
treatment and EPO RNA also was analyzed in the tumor and nontumor tissue. 
Case Report 
An 81-year-old man with angina pectoris was admitted to our hospital on May 20, 2007 for removal 
of a massive liver tumor on the right lobe. Laboratory data showed erythrocytosis (red blood count 
563 × 10
4/μl, hemoglobin level 16.4 g/dl, hematocrit 51.6%, and serum EPO 93.9 mU/ml; normal range 
12.5–34.5 mU/ml) and hypercholesterolemia (T-cho 363 mg/dl; he had been taking 10 mg atrovastatin 
calcium orally daily). Tests for hepatitis B and C virus markers were all negative. He rarely drank 
alcohol. Liver function test disclosed the following values: total bilirubin (TB) 0.6 mg/dl, aspartate 
aminotransferase 83 IU/l, alanine aminotransferase 37 IU/l, alkaline phosphatase 694 IU/l, serum 
albumin 3.4 g/dl, and PT-INR 1.08. There was a marked elevation of tumor markers such as AFP 
(900,100 ng/ml) and PIVKA-II (10,700 mAU/l). Ultrasonography and computed tomography showed a 
large mass measuring 12 cm in diameter in the right lobe of the liver (fig. 1a). The clinical diagnosis of 
this large mass was HCC. It was necessary to implant a coronary stent to treat severe angina pectoris, 
and anti-platelet therapy was carried out for at least one month to prevent restenosis of the stent. 
Therefore, prior to hepatic resection, transcatheter intraarterial injection of CDDP (I-A call: total 
80 mg) mainly to the right lobe was performed on May 30, 2007. After the CDDP injection, tumor size 
(fig. 1b) and serum AFP level (fig. 2a) decreased gradually. About three weeks after CDDP 
administration, along with the reduction of tumor size, hemoglobin level, serum EPO and T-cho also 
decreased, to 13.8 g/dl, 11.1 mU/ml and 247 mg/dl, respectively (fig. 2b). A right lobectomy was 
performed on July 31 after implantation of the coronary stent. The tumor was almost necrotic and 
minimum residual cancer was detected. This residual cancer was diagnosed as poorly to moderately 
differentiated HCC. Nonalcoholic steatohepatitis (NASH) with mild fibrosis also was diagnosed in the 
resected liver (fig. 3a, b). EPO expression was detectable by semiquantitative reverse transcription 
polymerase chain reaction (RT-PCR) in the residual tumor, but no expression was detected in the 
resected liver without cancer (fig. 3c). Additional intraarterial CDDP administration was performed 3, 6 
and 9 months after surgery. Up to now, recurrence of HCC and elevation of tumor markers have not 
been detected. 
Discussion 
Reports of HCC patients with paraneoplastic syndrome are not uncommon [1–6]. 
Four paraneoplastic syndromes have been reported in a single patient [1]. However, their 
prognosis has been poor except for rare successful cases treated with surgery and 
transarterial chemoembolization [2, 3]. Except for these rare cases, patients have died  
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soon after tumor detection without sufficient therapy [1, 3, 4–6]. In this report, an aged 
HCC patient with paraneoplastic syndrome and angina pectoris was treated successfully 
with combined neoadjuvant CDDP administration and surgery. This report is a rare case 
of HCC with paraneoplastic syndrome that was treated successfully; the markers of 
paraneoplastic syndromes could be monitored throughout the treatment. 
In this case, elevation of the serum level of EPO and cholesterol was detected. 
Matsuyama et al. [3] reported the detection of EPO in tumor cells by 
immunohistochemistry. In this study, expression of EPO was detected in the residual 
tumor but not in nontumorous liver tissue. This suggests that the tumor cells produced 
EPO. On the other hand, the mechanism whereby hyperlipidemia occurs cannot be 
explained clearly. Hirayama et al. [7] analyzed hepatoma-bearing rats with hyperlipidema 
and concluded that hypercholesterolemia was caused by increased cholesterol efflux from 
tumors as a result of activation of the liver X receptor α and overexpression of the sterol 
regulatory element-binding protein processing system contributing to activation of 
liver X receptor α by maintaining high oxysterol levels in tissue. These reports and 
associated data suggest that these markers may be used as tumor markers and that early 
detection of paraneoplastic syndrome can improve the prognosis of the patients. In fact, 
in this case, the hemoglobin level and serum levels of EPO and T-cho did indeed reflect 
tumor progression and were used as tumor markers. 
CDDP often has been used for the treatment of HCC. In this case CDDP was very 
effective. This may be a rare case, however the dramatic effect of CDDP suggests that this 
may become an option for similar high-risk patients. 
Recently, because patients at high risk for HCC have been followed up closely, small 
HCCs have been detected at an early date. Nevertheless, patients are often found with 
large HCCs. This patient was diagnosed with NASH by his resected liver and this suggests 
that patients with NASH also must be followed up carefully. This case also suggests that 
patients with paraneoplastic syndrome such as erythrocytosis or hyperlipidemia must be 
suspected of cancer, such as HCC. In these cases of early detection, the lives of some 
patients can be prolonged. 
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Fig. 1. Computed tomography before and after neoadjvant chemotherapy. a Before chemotherapy, a 
massive HCC measuring 12 cm in diameter occupied the right lobe of the liver. b At day 30 after 
neoadjuvant chemotherapy, the size of the tumor was reduced to 7 cm in diameter. 
 
 
 
Fig. 2. Clinical course of the patient. a Tumor markers (AFP, PIVKA-II) decreased after neoadjuvant 
chemotherapy. These two markers fell to within the normal range after surgery. b The levels of serum 
T-cho and EPO also decreased after neoadjuvant chemotherapy. These levels fell to within the normal 
range before surgery. 
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Fig. 3. Hematoxylin-eosin (HE) staining and RT-PCR analysis of the resected liver. a HE staining of the 
resected liver revealed that this patient suffered from NASH. Fatty change with chronic inflammation 
can be seen. Mallory’s body also was detected (arrow, original magnification ×400). b The residual liver 
tumor was moderately to poorly differentiated HCC. Many lymphocytes infiltrated the tumor. 
c Semiquantiative RT-PCR revealed that the residual cancer expressed RNA for EPO but the non-umor 
area did not. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used as an internal control. T = 
Tumor, N = nontumor. 
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